A Study Run at Multiple Study Sites to Test Whether the SAMANTA Questionnaire That is Used to Diagnose Heavy Menstrual Bleeding (HMB), Can Also be Used to Assess Changes of Severity of HMB in Women With HMB Who Are Treated During 12 Months With a Chronic Hormonal Treatment

Menorrhagia Clinical Trial

— SAMIRA  

Official title:

An Observational, Prospective, Multicentre Study to Assess the Sensitivity to Change of the SAMANTA Questionnaire in Women With Heavy Menstrual Bleeding (HMB)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03751800
• Other study ID #: 20061
• Status: Completed
• Start date: December 12, 2018
• Est. completion date: May 18, 2021

Study information

• Verified date: November 2023
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

A study run at multiple study sites in Spain to test whether the SAMANTA questionnaire that is used to diagnose heavy menstrual bleeding (HMB), can also be used to assess changes of severity of HMB in women with HMB who are treated during 12 months with a chronic hormonal treatment. Patients that are treated with chronic hormonal treatment as Levonorgestrel (trade name Mirena) or with a combination of estradiol valerate and dienogest (trade name Qlaira) or with Medroxyprogesterone acetate (trade name Progevera) and any new hormonal treatment marketed in Spain that has the indication for HMB in routine gynaecological practice are observed for 12 months in this study or for a shorter period in time in case of withdrawal. The study aims also to describe the overall satisfaction of women with their chronic hormonal treatment for HMB and how the women think their menstrual bleeding has changed. In addition the study aims to describe the changes of the score that is derived from the SAMANTA questionnaire in relation to Quality of Life. Quality of Life is measured with the SF36v2 questionnaire. The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 422
• Est. completion date: May 18, 2021
• Est. primary completion date: March 12, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Women in childbearing age, =18 years old, not intending to become pregnant during the next year.
• Women diagnosed with heavy menstrual bleeding or idiopathic menorrhagia according to medical criteria and based on clinical judgment.
• Women for whom the clinician decides, in agreement with the patient, to prescribe any of the available chronic hormonal treatments with the therapeutic indication of HMB in Spain (Mirena, Qlaira or Progevera).
• Women capable of reading and writing.
• Women who signed the informed consent.

Exclusion Criteria:

• Women with amenorrhea or menopause.
• Women with contraindications and warnings with the chronic hormonal treatment prescribed for HMB as per the summary of product characteristics (interaction with concomitant medication, etc.).
• Women receiving contraceptive hormonal therapy or using a copper intrauterine device.
• Women on hormone replacement therapy.
• Women with a history of malignancy.
• Women with degenerative diseases that could directly negatively impact their daily life.
• Women who have given birth within the previous 6 months.
• Women who are pregnant.
• Women participating in an investigational program with interventions outside of routine clinical practice.
• Women with psychiatric disorders who are unable to make decisions and follow instructions.
• Women with concomitant medication that may lead to changes in the bleeding pattern (e.g. antiplatelet and/ or anticoagulants).

Related Conditions & MeSH terms

• Hemorrhage
• Menorrhagia

Intervention

Drug:
• Chronic hormonal treatment
Drugs used in this study are described by the physicians during routine gynecological visits

Locations

Country	Name	City	State
Spain	Many locations	Multiple Locations

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Country where clinical trial is conducted

Spain, 

References & Publications (1)

Perello-Capo J, Rius-Tarruella J, Andeyro-Garcia M, Calaf-Alsina J. Sensitivity to Change of the SAMANTA Questionnaire, a Heavy Menstrual Bleeding Diagnostic Tool, After 1 Year of Hormonal Treatment. J Womens Health (Larchmt). 2023 Feb;32(2):208-215. doi: 10.1089/jwh.2022.0155. Epub 2022 Dec 22. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	SAMANTA questionnaire score	SAMANTA questionnaire: is a existing and validated tool has shown that it can be effectively used by gynaecologists to easily discriminate among women with and without HMB	Up to 12 months
Secondary	Overall satisfaction with the chronic hormonal treatment measured with a user satisfaction questionnaire		Up to 12 months
Secondary	Changes in menstrual bleeding pattern measured with a user satisfaction questionnaire		Up to 12 months
Secondary	Correlation between changes in SAMANTA score and changes in women's quality of life measured with SF36v2 questionnaire	SF36v2: Generic health questionnaire, which comprises five dimensions: mobility, self-care, usual activities, pain/ discomfort and anxiety/ depression	Up to 12 months

External Links

•   Click here to find results for studies related to Bayer products